DOI: http://dx.doi.org/10.17305/bjbms.2010.2712 | Full Text: [PDF]

Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine

Timur Cerić, Nermina Obralić, Lejla Kapur-Pojskić, Draženka Macić, Semir Bešlija, Anes Pašić, Šejla Cerić

Abstract


Adverse drug reactions still pose an important clinical problem. Dihydropyrimidine dehydrogenase (DPD) is an enzyme that regulates 5-FU quantities available for anabolic processes and hence affects its pharmacokinetics, toxicity and efficacy.

There are several studies describing a hereditary (pharmacogenetic) disorder in which individuals with absent or significantly reduced DPD activity may even develop a life-threatening toxicity following exposure to 5-FU. The most common mutation is known as the DPYD*2A or as the splice-site mutation (IVS14 + 1G A) leading to creation of a dysfunctional protein. An objective behind the study was to ascertain existence of the IVS14+ 1G A mutation among the population of Bosnia and Herzegovina. Our research has undeniably attested to existence of one heterozygote for the DPYD gene mutation, i.e. one heterozygote for IVS14 + 1 G > A, DPYD*2A mutation.


Keywords


pharmacogenetics; Dihydropyrimidine dehydrogenase; DPYD2A mutation

Full Text:

[PDF]

Refbacks

  • There are currently no refbacks.





Quick links for Authors:Quick links for Peer Reviewers:
  

Advanced online | Current Issue | Archives | Submit a manuscript | About the Journal

© Association of Basic Medical Sciences of FBIH, 1998-2018. Credits to Public Knowledge Project